Pd-0332991
| Title | Journal |
|---|---|
| Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. | Toxicology letters 20180701 |
| Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. | Blood 20160609 |
| Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. | Cancer research 20160301 |
| Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. | Leukemia 20160101 |
| Better Together: Targeted Combination Therapies in Breast Cancer. | Seminars in oncology 20151201 |
| FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20151101 |
| Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. | Journal of the National Cancer Institute 20151001 |
| Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. | Drug metabolism and disposition: the biological fate of chemicals 20150901 |
| Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. | The New England journal of medicine 20150716 |
| Palbociclib Extends Survival in Advanced Breast Cancer. | Cancer discovery 20150701 |
| Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. | Cancer 20150501 |
| Palbociclib: first global approval. | Drugs 20150401 |
| CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. | Clinical cancer research : an official journal of the American Association for Cancer Research 20150301 |
| The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. | The Lancet. Oncology 20150101 |
| CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. | Cancer research 20140715 |
| Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. | Pigment cell & melanoma research 20140701 |
| CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. | Genes & cancer 20140701 |
| Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. | Molecular cancer therapeutics 20140401 |
| MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. | Cell cycle (Georgetown, Tex.) 20140301 |
| Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. | Molecules (Basel, Switzerland) 20140217 |
| [Effect of PD0332991 on biological activity of hematopoietic stem cells in mice]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20140201 |
| Targeting cell cycle and hormone receptor pathways in cancer. | Oncogene 20131128 |
| Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. | British journal of cancer 20131112 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. | Anticancer research 20130801 |
| A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS. | Cancer biology & therapy 20130701 |
| Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. | Cell cycle (Georgetown, Tex.) 20130615 |
| Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20130601 |
| Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells. | Journal of neuro-oncology 20130101 |
| PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. | PloS one 20130101 |
| The requirement for cyclin D function in tumor maintenance. | Cancer cell 20121016 |
| Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. | Cancer cell 20121016 |
| Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. | Molecular cancer therapeutics 20121001 |
| Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120901 |
| CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. | Cell cycle (Georgetown, Tex.) 20120715 |
| Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. | Cell cycle (Georgetown, Tex.) 20120715 |
| p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. | Neuro-oncology 20120701 |
| The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway. | Cancer prevention research (Philadelphia, Pa.) 20120601 |
| Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. | Blood 20120517 |
| An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. | Journal of neuro-oncology 20120501 |
| Discovery pharmacokinetic studies in mice using serial microsampling, dried blood spots and microbore LC-MS/MS. | Bioanalysis 20120501 |
| Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. | Journal of the National Cancer Institute 20120321 |
| [(18)F]FLT-PET imaging does not always 'light up' proliferating tumor cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120301 |
| Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120115 |
| A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. | Cancer cell 20111115 |
| Retinoblastoma protein modulates the inverse relationship between cellular proliferation and elastogenesis. | The Journal of biological chemistry 20111021 |
| Quantitative analysis of PD 0332991 in mouse plasma using automated micro-sample processing and microbore liquid chromatography coupled with tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111001 |
| Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. | Biochemical and biophysical research communications 20110916 |
| Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment. | Molecular and cellular biology 20110701 |
| Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110701 |
| Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). | British journal of cancer 20110607 |
| Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. | Endocrine-related cancer 20110601 |
| A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer. | Oncogene 20110428 |
| Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110315 |
| [CDK4, a specific target in the treatment of lung adenocarcinomas mutated for KRAS]. | Medecine sciences : M/S 20101201 |
| Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry. | Journal of pharmaceutical and biomedical analysis 20101102 |
| RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. | Cell cycle (Georgetown, Tex.) 20101015 |
| Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives. | Journal of medicinal chemistry 20101014 |
| Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. | Oncogene 20100715 |
| A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. | Cancer cell 20100713 |
| Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. | Proceedings of the National Academy of Sciences of the United States of America 20100622 |
| Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. | Gastroenterology 20100501 |
| Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. | Cancer research 20100415 |
| The landscape of somatic copy-number alteration across human cancers. | Nature 20100218 |
| Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors. | European journal of medicinal chemistry 20100201 |
| Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. | Cancer research 20090515 |
| Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. | Blood 20090319 |
| Treatment of growing teratoma syndrome. | The New England journal of medicine 20090122 |
| Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090101 |
| PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. | Breast cancer research : BCR 20090101 |
| CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. | Breast cancer research : BCR 20090101 |
| A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. | Cancer research 20080715 |
| Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. | Blood 20070915 |
| Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues. | Cancer research 20070515 |
| Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. | Blood 20060901 |
| A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. | Cancer research 20060801 |
| Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition. | Journal of medicinal chemistry 20060629 |
| Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. | Molecular cancer therapeutics 20060501 |
| Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. | Current opinion in pharmacology 20050801 |
| Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. | Journal of medicinal chemistry 20050407 |
| Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. | Molecular cancer therapeutics 20041101 |
| Primary care pediatrics vs. family practice: a nonissue. | Israel journal of medical sciences 19830801 |